HBP Share Price

Open 1.50 Change Price %
High 1.55 1 Day 0.00 0.00
Low 1.50 1 Week 0.00 0.00
Close 1.55 1 Month -0.01 -0.64
Volume 4000 1 Year -0.49 -24.02
52 Week High 2.25
52 Week Low 1.40
HBP Important Levels
Resistance 2 1.60
Resistance 1 1.58
Pivot 1.53
Support 1 1.52
Support 2 1.50
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
SC 60.83 -0.44%
PRE 0.64 0.00%
PRE 0.64 0.00%
PRE 0.64 0.00%
More..
TSE Canada Top Gainers Stocks
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
TVI 0.02 100.00%
RN 0.11 22.22%
RN 0.11 22.22%
PWC 0.12 20.00%
PWC 0.12 20.00%
IMP 0.07 16.67%
IMP 0.07 16.67%
More..
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
AVP 0.07 -12.50%
AVP 0.07 -12.50%
AVP 0.07 -12.50%
AVP 0.07 -12.50%
NKO 0.08 -11.11%
NKO 0.08 -11.11%
NKO 0.08 -11.11%
TBL 0.95 -7.77%
BAA 0.24 -7.69%
More..

Helix BioPharma Corp (TSE: HBP)

HBP Technical Analysis 5
As on 5th Dec 2016 HBP Share Price closed @ 1.55 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.90 & Strong Sell for SHORT-TERM with Stoploss of 1.69 we also expect STOCK to react on Following IMPORTANT LEVELS.
HBP Target for December
1st Target up-side 1.69
2nd Target up-side 1.78
3rd Target up-side 1.88
1st Target down-side 1.41
2nd Target down-side 1.32
3rd Target down-side 1.22
HBP Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.helixbiopharma.com
HBP Address
HBP
305 Industrial Parkway South
Unit 3
Aurora, ON L4G 6X7
Canada
Phone: 905-841-2300
Fax: 905-841-2244
Interactive Technical Analysis Chart Helix BioPharma Corp ( HBP TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Helix BioPharma Corp
HBP Business Profile
Helix BioPharma Corp., a biopharmaceutical company, develops drugs for the prevention and treatment of cancer based on its proprietary technologies. The company focuses on the development of L-DOS47 that is in phase I/II clinical trial for the treatment of inoperable, locally advanced, and recurrent or metastatic non-small cell lung cancer; and Topical Interferon Alpha-2b, which has completed phase II study for the treatment of low-grade cervical lesions and ano-genital warts caused by human papilloma virus infections. It also offers DOS47, a patented oncology platform technology that derives a therapeutic pharmacological effect by acting upon a naturally occurring substance in the body. Helix BioPharma Corp. is based in Aurora, Canada.